Comparative Pharmacology
Head-to-head clinical analysis: ROGAINE FOR MEN versus ROGAINE EXTRA STRENGTH FOR MEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROGAINE FOR MEN versus ROGAINE EXTRA STRENGTH FOR MEN.
ROGAINE (FOR MEN) vs ROGAINE EXTRA STRENGTH (FOR MEN)
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation and increased cutaneous blood flow. It also stimulates hair follicles by prolonging the anagen phase and increasing follicular size via activation of prostaglandin synthesis and upregulation of vascular endothelial growth factor (VEGF).
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.
FDA-approved for androgenetic alopecia (male pattern hair loss) in men
Treatment of androgenetic alopecia (male pattern baldness) in men
1 mL of 5% solution applied topically to the scalp twice daily (total daily dose 2 mL).
1 mL of 5% minoxidil solution applied topically to the scalp twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4.2 hours (range 2.5–5.5 hours) in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is longer, correlating with its prolonged tissue binding.
Terminal elimination half-life is approximately 4.2 hours (range 3.5–5.0 hours) in healthy adults. Clinical context: Maintains steady-state concentrations with twice-daily topical application without significant accumulation.
Minoxidil is primarily metabolized in the liver by glucuronidation via UGT1A1 and UGT1A9 enzymes, as well as sulfation. A minor pathway involves N-oxidation. The major metabolite is minoxidil glucuronide, which is excreted renally.
Minoxidil is primarily metabolized by conjugation with glucuronic acid at the N-oxide position in the liver. CYP450 enzymes are minimally involved.
Approximately 60% of absorbed minoxidil is metabolized, primarily by conjugation with glucuronic acid. The remaining 40% is excreted unchanged in urine. Renal excretion is the major route, with unchanged drug and metabolites eliminated via the kidneys. Fecal excretion accounts for <3%.
Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination. Fecal excretion is minimal (<3%).
Approximately 20% bound to plasma proteins (albumin).
Approximately 20% bound to plasma proteins (primarily albumin).
Approximately 2.5–3.2 L/kg, indicating extensive distribution into tissues, including vascular smooth muscle (site of action) and hair follicles.
Apparent volume of distribution is approximately 2.5 L/kg, indicating extensive distribution into total body water and tissues.
Oral: Approximately 90% absorbed, but first-pass metabolism reduces systemic bioavailability to about 50% (range 30–70%). Topical: Systemic absorption is minimal (1.4% of applied dose) and does not produce clinically significant cardiovascular effects.
Topical: systemic bioavailability is low (approximately 1.4% of applied dose) due to poor percutaneous absorption. Oral: approximately 50% (not indicated for this formulation).
No dose adjustment required for renal impairment; minimal systemic absorption.
No dosage adjustment required for renal impairment; not systemically absorbed in significant amounts.
No dose adjustment required for hepatic impairment; minimal systemic absorption.
No dosage adjustment required for hepatic impairment; not systemically absorbed in significant amounts.
Not indicated for use in pediatric patients; safety and efficacy not established.
Safety and effectiveness in pediatric patients under 18 years have not been established.
No specific dose adjustment; apply 1 mL twice daily as in adults, monitor for local irritation.
No specific dosage adjustment; use with caution due to potential for increased systemic absorption from thinner skin.
No FDA black box warning.
No FDA boxed warning.
["Cardiovascular risks: May cause reflex tachycardia, fluid retention, and pericardial effusion, especially with systemic absorption.","Dermatological reactions: Local irritation, dermatitis, and rarely hypertrichosis on face or other body areas.","Ophthalmic effects: Blurred vision or eye irritation if accidentally sprayed into eyes.","Hypotension: Potential for orthostatic hypotension with excessive use.","Monitoring: Blood pressure and heart rate should be monitored in patients with known cardiovascular disease."]
["Cardiovascular risks such as tachycardia, fluid retention, and pericardial effusion with topical use are rare but possible.","May cause hypotension if accidentally ingested.","Avoid contact with eyes and broken skin.","Discontinue if scalp irritation occurs.","Use with caution in patients with hypertension or underlying cardiovascular disease."]
["Hypersensitivity to minoxidil or any component of the formulation.","Use on broken, irritated, or sunburned scalp.","Concomitant use of other topical or systemic vasodilators without medical supervision.","Severe underlying cardiovascular disease (e.g., unstable angina, recent myocardial infarction)."]
["Hypersensitivity to minoxidil or any component of the formulation.","Concomitant use with other topical agents on the scalp."]
Data Pending Review
Data Pending Review
None known. Minoxidil topical solution is not absorbed systemically to a significant degree; no food interactions have been reported. Alcohol content in the vehicle may cause irritation if ingested.
No known food interactions.
Minoxidil (Rogaine for Men) is Pregnancy Category C. First trimester: No adequate human studies, animal studies show fetal abnormalities at high doses. Second and third trimesters: Risk cannot be ruled out; avoid use due to potential for fetal harm including skeletal and cardiac defects.
Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the human dose. Human data are insufficient; risk is considered low but cannot be excluded. Use only if clearly needed during pregnancy. No specific trimester risks identified.
Minoxidil is excreted in human milk. M/P ratio unknown. Potential for severe adverse effects in nursing infants (e.g., hypotension, electrolyte disturbances). Breastfeeding not recommended during treatment.
Minoxidil is excreted in human milk following oral administration; however, following topical application, systemic absorption is minimal (1.4%). The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No dosage adjustment is recommended for topical minoxidil due to negligible systemic absorption. However, pregnancy is a contraindication; discontinue use.
No dose adjustment is necessary. Pharmacokinetic changes in pregnancy (e.g., increased blood volume, altered skin perfusion) are not expected to significantly alter the minimal systemic absorption of topical minoxidil. Use standard dosing: 1 mL twice daily to the scalp.
Category C
Category C
Minoxidil (ROGAINE FOR MEN) is a topical vasodilator that prolongs the anagen phase of hair follicles; response typically requires 4-6 months of consistent twice-daily application. It is more effective for vertex (crown) baldness than frontal loss. Advise patients that initial shedding may occur in first 2-6 weeks due to telogen phase synchronization. Use in patients with scalp psoriasis or dermatitis may enhance absorption and increase systemic effects. Contraindicated in patients with history of minoxidil hypersensitivity or unexplained scalp irritation.
Rogaine Extra Strength (5% minoxidil) is indicated for androgenetic alopecia in men. Onset of hair regrowth typically occurs after at least 4 months of twice-daily use; continued use is required to maintain effects. Discontinue if scalp irritation or unwanted facial hair growth occurs. Not effective for receding frontal hairline; primarily promotes vertex balding. May cause initial shedding of telogen hairs, which is a sign of efficacy.
Apply 1 mL of solution directly to dry scalp twice daily, not to hair. Do not use on sunburned, irritated, or broken skin.Expect a temporary increase in hair shedding during the first 2-6 weeks of use; this indicates drug is working.Visible results may take at least 4 months of consistent use; continue as directed for at least 1 year to assess efficacy.Discontinue use if scalp redness, itching, burning, or swelling occurs; report any chest pain, dizziness, or rapid heartbeat.Wash hands thoroughly after each application; avoid contact with eyes, nose, and mouth.
Apply 1 mL directly to the scalp in the affected area twice daily, not more often.Wash hands thoroughly after each application.Do not apply to wet hair or within 24 hours of using other scalp treatments.Results may take 4 months or longer; continued use is necessary to maintain regrowth.Initial hair shedding is normal and indicates new hair growth.Avoid contact with eyes; if accidental contact occurs, rinse with cool water.